418 related articles for article (PubMed ID: 26294695)
1. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms.
Mowat C; Digby J; Strachan JA; Wilson R; Carey FA; Fraser CG; Steele RJ
Gut; 2016 Sep; 65(9):1463-9. PubMed ID: 26294695
[TBL] [Abstract][Full Text] [Related]
2. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
Högberg C; Karling P; Rutegård J; Lilja M
Scand J Gastroenterol; 2017 Jan; 52(1):69-75. PubMed ID: 27623716
[TBL] [Abstract][Full Text] [Related]
3. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care.
Conroy S; Hale MF; Cross SS; Swallow K; Sidhu RH; Sargur R; Lobo AJ
J Clin Pathol; 2018 Apr; 71(4):316-322. PubMed ID: 28844038
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
5. Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study.
Turvill J; Aghahoseini A; Sivarajasingham N; Abbas K; Choudhry M; Polyzois K; Lasithiotakis K; Volanaki D; Kim B; Langlands F; Andrew H; Roos J; Mellen S; Turnock D; Jones A
Br J Gen Pract; 2016 Jul; 66(648):e499-506. PubMed ID: 27266863
[TBL] [Abstract][Full Text] [Related]
6. Use of faecal immunochemical testing as an alternative to faecal calprotectin in children.
Sandhu K; Naik S; Ayling RM
Ann Clin Biochem; 2021 May; 58(3):230-235. PubMed ID: 33412889
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
Summerton CB; Longlands MG; Wiener K; Shreeve DR
Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):841-5. PubMed ID: 12172403
[TBL] [Abstract][Full Text] [Related]
8. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders.
Lozoya Angulo ME; de Las Heras Gómez I; Martinez Villanueva M; Noguera Velasco JA; Avilés Plaza F
Gastroenterol Hepatol; 2017 Mar; 40(3):125-131. PubMed ID: 27260632
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
[TBL] [Abstract][Full Text] [Related]
10. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease.
Sipponen T; Kolho KL
Scand J Gastroenterol; 2010 Aug; 45(7-8):872-7. PubMed ID: 20377469
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of one or two faecal haemoglobin and calprotectin measurements in patients with suspected colorectal cancer.
Turvill J; Mellen S; Jeffery L; Bevan S; Keding A; Turnock D
Scand J Gastroenterol; 2018 Dec; 53(12):1526-1534. PubMed ID: 30621475
[TBL] [Abstract][Full Text] [Related]
12. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients.
Widlak MM; Thomas CL; Thomas MG; Tomkins C; Smith S; O'Connell N; Wurie S; Burns L; Harmston C; Evans C; Nwokolo CU; Singh B; Arasaradnam RP
Aliment Pharmacol Ther; 2017 Jan; 45(2):354-363. PubMed ID: 27910113
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers.
Widlak MM; Neal M; Daulton E; Thomas CL; Tomkins C; Singh B; Harmston C; Wicaksono A; Evans C; Smith S; Savage RS; Covington JA; Arasaradnam RP
Colorectal Dis; 2018 Dec; 20(12):O335-O342. PubMed ID: 30248228
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy.
von Roon AC; Karamountzos L; Purkayastha S; Reese GE; Darzi AW; Teare JP; Paraskeva P; Tekkis PP
Am J Gastroenterol; 2007 Apr; 102(4):803-13. PubMed ID: 17324124
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease.
Zhang W; Wong CH; Chavannes M; Mohammadi T; Rosenfeld G
BMJ Open; 2019 Apr; 9(4):e027043. PubMed ID: 30987989
[TBL] [Abstract][Full Text] [Related]
17. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.
Walker GJ; Moore L; Heerasing N; Hendy P; Perry MH; McDonald TJ; Debenham T; Bethune R; Bewshea C; Hyde C; Heap GA; Singh A; Calvert C; Kennedy NA; Goodhand JR; Ahmad T
Aliment Pharmacol Ther; 2018 Apr; 47(8):1103-1116. PubMed ID: 29508423
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.
Amcoff K; Stridsberg M; Lampinen M; Magnuson A; Carlson M; Halfvarson J
Scand J Gastroenterol; 2017 Mar; 52(3):344-350. PubMed ID: 27881032
[TBL] [Abstract][Full Text] [Related]
19. Measurement of faecal haemoglobin with a faecal immunochemical test can assist in defining which patients attending primary care with rectal bleeding require urgent referral.
Digby J; Strachan JA; McCann R; Steele RJ; Fraser CG; Mowat C
Ann Clin Biochem; 2020 Jul; 57(4):325-327. PubMed ID: 32482080
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view.
McFarlane M; Chambers S; Malik A; Lee B; Sung E; Nwokolo C; Waugh N; Arasaradnam R
BMJ Open; 2016 Jun; 6(6):e011041. PubMed ID: 27266773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
